Table 2.

PI3K/AKT activity and clinical feature/outcome of patients in the roflumilast trial

	UPN	Diagnosis	Days on trial	No of cycles	Best response
PI3K/AKT suppressors	02	CLL	190	8	Stable disease
	03	MZL/DLBCL	315	13	Partial response
	04	CLL	49	2	Progressed
	07	ALL/LL	127	5	Stable disease
	09	MM	98	4	Stable disease
PI3K/AKT non-suppressors	05	DLBCL	28	1	Progressed
	06	MCL	139	5	Stable disease
	08	MM	105	4	Stable disease
	10	FL	29	1	Not evaluable

UPN – Unique patient number; CLL – chronic lymphocytic leukemia, MZL – marginal zone lymphoma; DLBCL – diffuse large B cell lymphoma; ALL/LL – acute lymphoid leukemia/lymphoblastic lymphoma; MM – multiplemyeloma; FL – follicular lymphoma;